4-aminopyridine and Dyskinesia Syndromes studies

Research Excerpts

Excerpt	Relevance	Reference
"Twelve temperature-sensitive male patients with multiple sclerosis and 5 normal men were monitored before, during, and after the intravenous injection of 7 to 35 mg of 4-aminopyridine (4-AP) in 1- to 5-mg doses, every 10 to 60 minutes."	7.67	4-Aminopyridine improves clinical signs in multiple sclerosis. ( Davis, FA; Faut, M; Schauf, CL; Stefoski, D, 1987)
"A previous phase 3 study showed significant improvement in walking ability in multiple sclerosis (MS) patients treated with oral, extended-release dalfampridine (4-aminopyridine) 10mg twice daily."	5.14	A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. ( Blight, AR; Brown, TR; Cohen, R; Edwards, KR; Goodman, AD; Krupp, LB; Marinucci, LN; Schapiro, RT, 2010)
"Twelve temperature-sensitive male patients with multiple sclerosis and 5 normal men were monitored before, during, and after the intravenous injection of 7 to 35 mg of 4-aminopyridine (4-AP) in 1- to 5-mg doses, every 10 to 60 minutes."	3.67	4-Aminopyridine improves clinical signs in multiple sclerosis. ( Davis, FA; Faut, M; Schauf, CL; Stefoski, D, 1987)
"The Ashworth scale of spasticity was significantly (p2 < 0."	2.69	Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. ( Brunnemann, SR; Delaney, GA; Hayes, KC; Hsieh, JT; Mason, D; Potter, PJ; Segal, JL; Tierney, DS, 1998)

Research

Studies (6)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Symbol Digit Modalities Test

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (16.67)	18.7374
1990's	1 (16.67)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (33.33)	24.3611
2020's	2 (33.33)	2.80

Authors	Studies
Simon, CM	1
Blanco-Redondo, B	1
Buettner, JM	1
Pagiazitis, JG	1
Fletcher, EV	1
Sime Longang, JK	1
Mentis, GZ	1
Satchidanand, N	1
Drake, A	1
Smerbeck, A	1
Hojnacki, D	1
Kolb, C	1
Patrick, K	1
Weinstock-Guttman, B	1
Motl, R	1
Benedict, RH	1
Bennett, SE	1
Goodman, AD	1
Brown, TR	1
Edwards, KR	1
Krupp, LB	1
Schapiro, RT	1
Cohen, R	1
Marinucci, LN	1
Blight, AR	1
Potter, PJ	1
Hayes, KC	1
Segal, JL	1
Hsieh, JT	1
Brunnemann, SR	1
Delaney, GA	1
Tierney, DS	1
Mason, D	1
Stefoski, D	1
Davis, FA	1
Faut, M	1
Schauf, CL	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effects of Dalfampridine on Cognition in Multiple Sclerosis[NCT02006160]	Phase 2/Phase 3	61 participants (Actual)	Interventional	2011-12-31	Completed
Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)[NCT01975324]	Phase 4	20 participants (Actual)	Interventional	2013-07-31	Completed
Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking[NCT03847545]		48 participants (Actual)	Interventional	2018-12-12	Completed
Short and Long Term Fampridine Treatment in Persons With Multiple Sclerosis: Cognitive and Motor Performances[NCT02849782]	Phase 4	89 participants (Actual)	Interventional	2014-02-04	Completed
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis[NCT00483652]	Phase 3	240 participants (Actual)	Interventional	2007-05-31	Completed
RETRAP - A Double Blind, Randomized, Placebo Controlled Study of the Effect of the Combination of Resistance Training and Prolonged Release Fampridine in Patients With Multiple Sclerosis[NCT02143167]	Phase 4	40 participants (Actual)	Interventional	2014-05-31	Completed
Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra[NCT01656148]	Phase 4	108 participants (Actual)	Interventional	2012-06-30	Completed
Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2[NCT01543750]	Phase 2	0 participants (Actual)	Interventional		Withdrawn
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The Symbol Digit Modalities Test is a measure of cognitive processing speed. The outcome is the total number of correct digit substitutions in 90 seconds, with a possible total range of 0-120. Higher values reflect a better score/outcome than lower scores. (NCT02006160)
Timeframe: Week 0, Week 12

Change in Lower Extremity Manual Muscle Test [LEMMT]

Intervention	score on a scale (Mean)
	Week 0	Week 12
Control	35.06	38.63
Treatment	41.18	45.05

Evaluator rated strength in hip flexors, knee flexors, knee extensors, and ankle dorsiflexors on the following scale: best value = 5.0 (normal muscle strength), worst value = 0.0 (absence of any voluntary contraction). A positive shift in LEMMT score shows improvement in strength. Change in LEMMT scores for the secondary efficacy measure was found by averaging the LEMMT scores on days 14, 28, 42, and 56 (double-blind treatment period) and subtracting the baseline LEMMT score. (NCT00483652)
Timeframe: Days -21, -14, -7, 0, 14, 28, 42, 56, 63, 77

Responders Based Upon the Timed 25-Foot Walk [T25FW]

Intervention	units on a scale (Mean)
Fampridine-SR 10 mg b.i.d. Treatment	0.09
Placebo Treatment	0.04

A responder is a patient who showed faster walking speed for at least 3 visits out of a possible 4 during the double-blind period than the maximum value achieved in the 5 non-double-blind no-treatment visits (4 before the double-blind period and one after) (NCT00483652)
Timeframe: Days -21, -14, -7, 0, 14, 28, 42, 56, 63, 77

Article	Year
Dalfampridine benefits ambulation but not cognition in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2020, Volume: 26, Issue:1 Topics: 4-Aminopyridine; Adult; Cognitive Dysfunction; Double-Blind Method; Female; Humans; Male; Middle Age	2020
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 2010, Volume: 68, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Administration Schedu	2010
Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. Journal of neurotrauma, 1998, Volume: 15, Issue:10 Topics: 4-Aminopyridine; Adult; Analysis of Variance; Chi-Square Distribution; Cross-Over Studies; Delayed-A	1998

Article	Year
Chronic Pharmacological Increase of Neuronal Activity Improves Sensory-Motor Dysfunction in Spinal Muscular Atrophy Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2021, 01-13, Volume: 41, Issue:2 Topics: 4-Aminopyridine; Animals; Cell Death; Mice; Mice, Knockout; Motor Neurons; Movement Disorders; Muscu	2021
Fampridine: Long-term benefits in walking in multiple sclerosis. Neurology, 2017, 02-28, Volume: 88, Issue:9 Topics: 4-Aminopyridine; Humans; Movement Disorders; Multiple Sclerosis; Potassium Channel Blockers; Walking	2017
4-Aminopyridine improves clinical signs in multiple sclerosis. Annals of neurology, 1987, Volume: 21, Issue:1 Topics: 4-Aminopyridine; Adult; Aminopyridines; Flicker Fusion; Humans; Ion Channels; Male; Middle Aged; Mov	1987
4-Aminopyridine improves clinical signs in multiple sclerosis. Annals of neurology, 1987, Volume: 21, Issue:1 Topics: 4-Aminopyridine; Adult; Aminopyridines; Flicker Fusion; Humans; Ion Channels; Male; Middle Aged; Mov	1987
4-Aminopyridine improves clinical signs in multiple sclerosis. Annals of neurology, 1987, Volume: 21, Issue:1 Topics: 4-Aminopyridine; Adult; Aminopyridines; Flicker Fusion; Humans; Ion Channels; Male; Middle Aged; Mov	1987
4-Aminopyridine improves clinical signs in multiple sclerosis. Annals of neurology, 1987, Volume: 21, Issue:1 Topics: 4-Aminopyridine; Adult; Aminopyridines; Flicker Fusion; Humans; Ion Channels; Male; Middle Aged; Mov	1987

4-aminopyridine and Dyskinesia Syndromes